Arcellx Tender Offer Extended by Gilead as Only 7.5% of Shares Submitted
summarizeSummary
Gilead Sciences has extended the expiration of its tender offer to acquire Arcellx (ACLX) until April 24. This procedural update follows the previously announced $7.8 billion acquisition deal in February, which was also detailed in Gilead's recent 10-K filing. A significant detail is that only approximately 7.5% of Arcellx's outstanding shares have been validly tendered as of Tuesday, necessitating this extension. While the transaction is still expected to close during the second quarter, the low initial tender rate introduces a degree of uncertainty regarding the smooth and timely completion of the deal for Arcellx shareholders. Traders will monitor subsequent tender offer updates for signs of increased participation or further delays.
At the time of this announcement, ACLX was trading at $114.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $47.86 to $114.94. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.